Central Nervous System Diseases  >>  ropinirole IR  >>  Phase 4
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ropinirole IR / Generic mfg.
NCT00399477: A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease

Completed
4
200
US
rasagiline mesylate, Rasagiline mesylate plus Mirapex, Rasagiline mesylate with Levodopa, Rasagiline mesylate with Requip
Teva Neuroscience, Inc.
Parkinson's Disease
07/07
07/07
NCT00485069: REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study

Completed
4
123
Japan
ROP, ROP+L-Dopa
GlaxoSmithKline
Parkinson Disease, Parkinson's Disease
12/09
12/09
NCT00144300: Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients

Completed
4
246
US
Mirapex, Requip
Boehringer Ingelheim
Parkinson Disease
09/10
 
NCT01711866: A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease

Completed
4
87
US, RoW
Rotigotine, Neupro
UCB BIOSCIENCES GmbH, Otsuka Pharmaceutical Co., Ltd.
Advanced Idiopathic Parkinson's Disease
03/13
03/13
TANDEM-662 , NCT01485172: A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease

Completed
4
186
US, Europe, RoW
ropinirole monotherapy, placebo monotherapy
GlaxoSmithKline
Parkinson Disease
04/14
04/14
TANDEM-569 , NCT01494532: A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease

Completed
4
352
US, Europe, RoW
ropinirole/L-dopa, placebo/L-dopa
GlaxoSmithKline
Parkinson Disease
11/14
11/14

Download Options